NASDAQ · GRAL
Healthcare · Medical - Diagnostics & Research
$82.50
Up+$2.91 (+3.66%)
Updated Aug 28, 2026, 7:09 AM
SID Score
6.1/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GRAL closed at $82.50 after 21 trading sessions, up 15.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $79.00 | $85.49 | $78.00 | $82.50 | 742.99K |
| Aug 26, 2026 | $80.88 | $82.25 | $78.335 | $79.59 | 396.87K |
| Aug 25, 2026 | $78.24 | $84.49 | $76.63 | $82.54 | 658.69K |
| Aug 24, 2026 | $81.87 | $81.87 | $75.6101 | $76.58 | 381.02K |
| Aug 21, 2026 | $78.88 | $80.76 | $76.15 | $79.54 | 605.06K |
| Aug 20, 2026 | $73.77 | $81.8506 | $73.77 | $77.97 | 1.35M |
| Aug 19, 2026 | $73.56 | $77.125 | $72.20 | $73.96 | 1.1M |
| Aug 18, 2026 | $69.89 | $73.00 | $68.0101 | $70.89 | 533.1K |
| Aug 17, 2026 | $67.30 | $71.195 | $66.99 | $69.95 | 776.64K |
| Aug 14, 2026 | $67.98 | $68.71 | $66.3509 | $67.87 | 433.18K |
| Aug 13, 2026 | $68.94 | $69.99 | $67.34 | $68.24 | 529.39K |
| Aug 12, 2026 | $75.65 | $76.00 | $68.69 | $68.94 | 565.52K |
| Aug 11, 2026 | $75.10 | $76.44 | $73.70 | $75.48 | 575.77K |
| Aug 10, 2026 | $69.27 | $76.00 | $68.90 | $74.84 | 1.39M |
| Aug 7, 2026 | $65.00 | $69.54 | $63.40 | $69.48 | 1.64M |
| Aug 6, 2026 | $68.00 | $70.455 | $60.76 | $63.40 | 1.88M |
| Aug 5, 2026 | $72.89 | $74.74 | $71.93 | $74.18 | 514.19K |
| Aug 4, 2026 | $71.23 | $73.00 | $69.17 | $72.70 | 532.57K |
| Aug 3, 2026 | $69.53 | $71.51 | $66.65 | $70.27 | 366.29K |
| Jul 31, 2026 | $71.50 | $71.57 | $67.16 | $68.56 | 560.43K |
| Jul 30, 2026 | $65.05 | $71.45 | $64.315 | $71.14 | 546.42K |
The latest Smart Investors Daily articles mentioning GRAL.
GRAL research
Company profile and research snapshot.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 15, 2026 | Mizuho | Neutral | — |
| Jun 5, 2026 | Goldman Sachs | Neutral | — |
| May 6, 2026 | Piper Sandler | Neutral | — |
| May 6, 2026 | TD Cowen | Buy | — |
| Apr 10, 2026 | Mizuho | Neutral | — |
No generated briefing is available yet.
Yahoo · Aug 14, 2026
GRAIL (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin said the company’s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices. Speaking at the Canaccord Genuity Growth Conference
Yahoo · Aug 13, 2026
Galleri volume jumped 35% year over year on physician adoption and digital partnerships.
SeekingAlpha · Aug 12, 2026
GRAIL (GRAL) nears a binary FDA decision on Galleri; learn key catalysts, MCED upside, cash/financing risks, and what September AdCom may meanâread the full analysis here.
SeekingAlpha · Aug 11, 2026
Guardant Health, Inc. is rated a Buy and is experiencing robust growth, driven by its MRD and screening businesses. Read more on GH stock here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRAL.
